Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.

CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down

CVS Health Corp (NYSE:CVS) reported a near doubling in profits over 2023 on Wednesday but cut guidance for the year ahead on the prospect of higher medical costs. Adjusted earnings per share will likely sit at US$8.30 for 2024, the healthcare firm said in a full-year earnings release, rather than as previously anticipated at US$8.50.

CVS Health sees profit nearly double but cuts guidance

CVS Health Corp (NYSE:CVS) stock is on the rise today, after better-than-expected fourth-quarter earnings of $2.12 per share and despite the healthcare giant's disappointing 2024 forecast.

CVS Health Posts Upbeat Profits, Cuts Forecast

The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, CVS Health (CVS) Q4 Earnings: A Look at Key Metrics

The healthcare company's revised earnings projections are likely to add to investor uncertainty about the Medicare Advantage business.

CVS Health Cuts 2024 Guidance Due to Higher Medical Costs

CVS Health reported net income of $2 billion thanks to double-digit percentage growth in the company's healthcare benefits and services businesses that included contributions from a big boost in Obamacare enrollment.

CVS Health Profits Hit $2 Billion As Company Benefits From Obamacare And New Businesses

Shares of CVS Health Corp. CVS, +1.82% fell 0.3% in premarket trading Wednesday, after the drugstore chain and health care services company's fourth-quarter results beat expectations by wide margins, but lowered its full-year outlook because of “elevated medical cost trends.” Net income fell to $2.05 billion, or $1.58 a share, from $2.33 billion, or $1.77 a share, in the year-ago period.

CVS' stock slips after earnings beat by a wide margin but full-year outlook was cut due to higher medical costs

CVS Health lowered its adjusted profit forecast for 2024 on Wednesday after an increase in medical care among older adults in the United States drove up fourth-quarter costs at its insurance business.

CVS cuts 2024 profit forecast on elevated medical costs

WOONSOCKET, R.I. , Feb. 7, 2024 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2023.

CVS HEALTH REPORTS FOURTH QUARTER AND FULL-YEAR 2023 RESULTS

General Motors

LyondellBasell Industries

Since betting on the individual companies of the Standard and Poor's 500 offers a solid chance for long-term profitability, it stands to reason that going for undervalued S&P 500 stocks could potentially net you robust returns. In a way, it's like having your cake and eating it too.

The 3 Most Undervalued S&P 500 Stocks to Buy in February 2024

The company is a major player in the Medicare Advantage business, along with Humana and UnitedHealth.

CVS Health Earnings Are Soon. Medicare Advantage Will Be in Focus.

Discover

eBay

Altria

Stellantis N.V. 

United Continental Hlds

The “Magnificent Seven” stocks may garner the lion's share of market attention right now, but while there may be strong potential with some of “Mag 7” names, check out opportunities making far fewer headlines, like undervalued large-cap stocks. Although there are many large-cap value stocks that are “value traps,” or stocks trading at a low valuation that fail to perform well because of growth issues or other types of headwinds, there are stocks that are both undervalued, and that have catalysts in place that could help bridge the valuation gap.

The 7 Most Undervalued Large-Cap Stocks to Buy in February 2024

Bank of America

AT&T

As we enter February 2024, the stock market continues to power ahead, led by Big Tech. However, pockets of overvaluation are appearing, especially with the technology sector trading at 27.5 times the next twelve-month earnings.

The 3 Most Undervalued Long-Term Stocks to Buy in February 2024

Evaluate the expected performance of CVS Health (CVS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Exploring Analyst Estimates for CVS Health (CVS) Q4 Earnings, Beyond Revenue and EPS

CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVS Health (CVS) Earnings Expected to Grow: Should You Buy?

Carriage Services

Titan Machinery

While some of the heavily hyped enterprises of last year continue to do well this month, investors ought to consider ideas for undervalued stocks January 2024. True, nothing technically stops a security from rising and rising.

Wall Street Favorites: 3 Undervalued Stocks With Strong Buy Ratings for January 2024

CVS Health Corp (NYSE:CVS) stock was last seen up 0.6% at $73.40, extending a bounce off the $70 level.

Is the Worst Over for CVS Health Stock?

In the closing of the recent trading day, CVS Health (CVS) stood at $73, denoting a +1.4% change from the preceding trading day.

CVS Health (CVS) Advances While Market Declines: Some Information for Investors

The two investments will reduce the company's carbon footprint by nearly 114,000 metric tons annually WOONSOCKET, R.I. , Jan. 25, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced two agreements that total 264,000-megawatt hours with Constellation to purchase zero-emission, renewable energy equivalent to the annual electricity use of nearly 1,000 CVS Health locations in California, Washington, D.C.

CVS Health adds two new renewable energy projects with Constellation

Tyson Foods

Upstart Holdings

Tyson Foods drops CVS for startup PBM offering drug price transparency

Tyson Foods drops CVS for upstart pharmacy benefit manager, as industry upheaval over cost concerns spreads

American Tower

Alexandria Real Estate Equities

Chevron

DTE Energy

Diamondback Energy

Host Hotels & Resorts

Coca-Cola

NiSource

Philip Morris

Vici Properties

Analysts' top-rated dividend stocks in the S&P 500 yielding at least 3% include blue-chip stalwarts such as Coca-Cola, CVS Health and Chevron.

Analysts' Top S&P 500 Dividend Stocks to Buy Now

Loyalty programs have become a ubiquitous part of the retail landscape, offering consumers enticing rewards and incentives for sticking with their favorite brands. However, as retailers expand their offerings, the proliferation of multiple loyalty programs can complicate the consumer experience and pose challenges for both customers and retailers.

CVS Loyalty Chief Says Program Overhaul Driven by Consumer Desire to Keep It Simple

CVS Health Corporation's recent acquisitions have transformed the company into a leader in the healthcare services industry. Despite a decrease in COVID-19 vaccination rates and a revision of its full-year EPS guidance, CVS is expected to achieve reasonable growth. CVS introduced CostVantage, a drug pricing program aimed at providing greater transparency and potentially lowering drug prices.

CVS Health: Back In The Buy Column

Cigna

Humana

UnitedHealth Group

A sharp spike in hospital and doctor office visits among older Americans is raising questions about the program.

Humana and Other Insurers Bet Big on Medicare Advantage. Now the Risks Are Coming Into Focus.

Humana slashed its Q4 earnings outlook on higher medical costs and warned about weak Medicare Advantage enrollment.

News for CVS Health Stock (CVS)